摘要
目的评价氨苄西林-舒巴坦组(A组)、头孢哌酮组(B组)、左氧氟沙星组(C组)三种方案对治疗社区获得性肺炎药物经济学成本与效果。方法采用回顾性研究方法,运用成本-效果分析法对三种治疗方案进行成本与效果分析。结果三种治疗方案中,A组、B组、C组总成本分别为1770.96元、1896.00元、1153.86元,治愈率分别为46.2%,61.5%,69.2%,每增加1个单位效果A组与B组比C组需多花成本分别为28.49元和52.45元。结论C组为治疗社区获得性肺炎的较佳治疗方案,通过成本-效果分析能优化治疗方案、指导合理用药,提高临床疗效。
OBJECTIVE To evaluate the cost-effectiveness of three therapeutic schemes, ampicillin-sulbactam injection（A） , cefoperazone injection（B） and levofloxacin injection（C） in treatment of the community acquired pneumonia infections. METHODS Compared the cost and effectiveness of three therapeutic schemes, by usiag pharmaeoeeonomic cost-effectiveness analysis of retrospective study. RESULTS The total costs of A,B and C schemes were RMB 1770.96,1896.00 and 1153.86 yuans, respectively, and the effective ratios were 46.2% ,61.5% and 67.2% ,respectively. An increase of 1% effective rate in group C saved RMB 28.49 and 52.45 yuans in comparison with that in group A and B. CONCLUSION According to the evalution with pharmacoeconomic cost-effectiveness analysis, the group C is the best one for treating the community acquired pneumonia infection. The cost-effective analysis play an important role in optimizing therapeutic scheme, guiding rational use of drug and rising effective.
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2005年第4期343-345,共3页
Chinese Journal of Modern Applied Pharmacy
关键词
社区获得性肺炎
药物经济学
成本-效果分析
community acquired pneumonia （CAP）
pharmacoeconomics
cost-effectiveness analysis （ CEA ）
